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of Nonsynonymous SNVs with a Consensus
Deleteriousness Score, Condel
Abel Gonza´lez-Pe´rez1,* and Nuria Lo´pez-Bigas1,*
Several large ongoing initiatives that profit from next-generation sequencing technologies have driven—and in coming years will
continue to drive—the emergence of long catalogs of missense single-nucleotide variants (SNVs) in the human genome. As a conse-
quence, researchers have developed various methods and their related computational tools to classify these missense SNVs as probably
deleterious or probably neutral polymorphisms. The outputs produced by each of these computational tools are of different natures and
thus difficult to compare and integrate. Taking advantage of the possible complementarity between different tools might allow more
accurate classifications. Here we propose an effective approach to integrating the output of some of these tools into a unified classifica-
tion; this approach is based on aweighted average of the normalized scores of the individualmethods (WAS). (In this paper, the approach
is illustrated for the integration of five tools.) We show that this WAS outperforms each individual method in the task of classifying
missense SNVs as deleterious or neutral. Furthermore, we demonstrate that this WAS can be used not only for classification purposes
(deleterious versus neutral mutation) but also as an indicator of the impact of the mutation on the functionality of the mutant protein.
In other words, it may be used as a deleteriousness score of missense SNVs. Therefore, we recommend the use of this WAS as a consensus
deleteriousness score of missense mutations (Condel).Introduction
More than a dozen computational tools aimed at predict-
ing the effect of missense single-nucleotide variants
(SNVs) on protein function have been developed in the
past ten years, as the advances in high-throughput DNA
sequencing techniques opened the door to massive inter-
pretation of individual sequence variants. Large ongoing
initiatives, such as The Cancer Genome Atlas (Cancer
Genome Atlas Network, 2008),1 the International Cancer
Genome Consortium,2 and the 1000 Genomes Project
Consortium,3 as well as the sequencing of genomes of
patients affected by rare diseases,4–6 are producing compre-
hensive catalogs of mutations in the human genome.
Therefore, the need to determine whether those variants
correspond to polymorphisms in human populations or
whether they are involved in the development of diseases
will cause a continuous growth in the demand for such
methods and tools in the next few years.
The main objective of the tools that investigate the
impact of nonsynonymous SNVs on protein function is
to sort these mutants into those that are probably delete-
rious and those that encode neutral polymorphisms. As
a general rule, these tools are based on the constraints
imposed on amino acid changes in different regions of
the protein. These changes can be discovered through
the use of evolutionary information. Alternatively, some
of the tools directly assess the probable effect of the
mutation on the activity of the mutant protein.7–23 Indi-
vidual SNVs are subsequently sorted via scoring func-
tions,9,12–15,19,23 Bayesian classifiers,7 or machine learning
algorithms.11,20 Some of them are available to the user1Research Programme on Biomedical Informatics, Universitat Pompeu Fabra, Pa
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and run locally. Moreover, diverse datasets of mutations
have been employed for benchmarking the performance
of different methods. As a consequence, the user normally
finds it difficult to compare, complement, and integrate
their outputs.
In this paper, we describe our work to design amethod to
integrate the output of some of these predictive tools. To
implement the method, we combined five predictive tools,
Log R Pfam E-value (Logre),9 MAPP,8,19 Mutation Assessor
(Massessor),18 Polyphen2 (PPH2),7 and SIFT,13–15 into
a unified classification. First, we used these five methods
to score and classify HumVar, a comprehensive dataset of
deleterious and neutral mutations compiled elsewhere.7
Then, we combined the outputs of the five methods in
four different ways. We found that a weighted average of
the normalized scores (WAS) of the five methods outper-
forms each individual tool—and the other three
combining operations assayed—in the task of classifying
SNVs as deleterious or neutral. The process of integrating
the scores of individual methods in theWAS uses the prob-
abilities of the complementary cumulative distribution of
scores produced by eachmethod to compute their weights.
The score of each method is thus penalized in an inverse
manner with respect to its confidence. TheWAS accurately
classified 88.2% of the mutations in HumVar. The accuracy
of the WAS on a second dataset of deleterious and neutral
mutations compiled by the same group attained 89.6%.
Furthermore, we demonstrate that the WAS of cancer
mutations changes significantly with their recurrence
and that it correlates well with the decrease in biological
activity of experimentally assayed TP53 (MIM 191170)rc de Recerca Biome`dica de Barcelona, c/ Dr. Aiguader, 88, E-08003 Barcelona
-B.)
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Table 1. Datasets Used in the Study
HumVar HumDiv Cosmic Recurrence p53 Mutants
Positives 12405 deleterious mutations
collected from UniProt
3155 disease-relatedmutations
collected from OMIM
cancer-related mutations
divided in four groups
by degree of recurrence
(see text)
2312 mutants divided in
bins by percent of
transcription activation at four
yeast promoters with respect
to wild-type
(see text)
Negatives 8257 common
polymorphisms collected
from Swiss-Prot
6321 orthologous changes
in proteins in the positive set
Source Polyphen27 Cosmic database24,25 IARC TP53 database31
Use in the study design and evaluation of integrated scores correlation between WAS and
recurrence
correlation between WAS and
decrease in biological activitymutants. Therefore, we hypothesize that it could serve as
a good predictor of the impact of missense mutations on
the biological activity of proteins.
In conclusion, we propose that the results of different
methods aimed at predicting the outcome of missense
SNVs may be readily and effectively combined into an
integrated output to produce a better classifier than the
individual methods. Specifically, we recommend that
a WAS be used to carry out this integration. We regard
the resulting index as a consensus deleteriousness score
of missense mutations (Condel). At the bottom of the
Discussion section, we explain how to calculate the Con-
del. Moreover, a PERL script that can compute it from
the individual scores of a set of SNVs is available at our
website (see Web Resources section), along with instruc-
tions for employing it. Furthermore, the Condel, which
reflects the coherence of different methods of classifying
missense SNVs, can provide some insight into the impact
of the mutation on the biological activity of the proteins.Material and Methods
Datasets
We used four datasets obtained from different sources (Table 1).
First, we used two datasets composed of positive and negative
examples to run five programs aimed at separating deleterious
from neutral missense SNVs and assessing the performance of
different ways to integrate their outputs (see below). These two
sets, named HumVar and HumDiv, were obtained from the web-
site of PPH2, one of the programs included in the study. The
Polyphen team originally compiled them to benchmark their
program.7 HumVar is composed of 12,405 deleterious mutations
and 8257 common polymorphisms, whereas HumDiv contains
3155 disease-related mutations and 6321 amino acid changes
observed in mammalian orthologous proteins. For the sake of
clarity, in this paper we refer to the positive and negative examples
in these two datasets as deleterious and neutral mutations, respec-
tively.
The remaining two datasets contained only deleterious muta-
tions, and we used them to assess whether the WAS correlated
with the recurrence of cancer mutations and with the degree of
impairment of the biological activity caused by the mutations.
The third dataset consisted of four disjointed subsets of the
Cosmic database,24,25 release 49, sampled at increasing degrees
of recurrence, as follows: 9543 mutations appearing in only one
cancer sample; 1791 mutations in two, three, or four cancerThe Amsamples; 561 mutations in five to nine cancer samples; and
745 mutations in ten or more cancer samples. Finally, the fourth
dataset was composed of 2312 TP53 mutants and their associated
biological activity data measured as the trans-activation of tran-
scription at four yeast promoters.26,27 The mutations were
grouped in ten bins according to the fraction of the biological
activity of the wild-type protein retained by the mutants.
Running Predictive Tools
Two of the tools (SIFT and PPH2) receive as input the identifier (or
sequence) of the mutant protein, the position of the mutation,
and the wild-type andmutant amino acids. They internally search
for orthologous and paralogous proteins from a given database
and construct and refine a multiple-sequence alignment, which
they use as the starting point to calculate the score for the amino-
macid substitution. Therefore, we downloaded them from their
respective websites and installed and ran them locally by using
just PERL scripts to control their inputs from the four datasets
and their outputs.We followed all indications from the developers
when we ran the tools.
We also downloaded the MAPP tool from its website. This tool
receives a multiple-sequence alignment as an input and calculates
scores for all possible substitutions at all positions of the align-
ment where at least 50% of the sequences are represented.19
Hence, we implemented a PERL pipeline to automatically recover
all plausible orthologous and paralogous proteins from the En-
sembl-compara database28 and built a multiple-sequence align-
ment and a phylogenetic tree from them by using ProbCons29
and ClustalW,30 respectively, which were then used by MAPP. Its
output file was parsed to retrieve the score corresponding to the
mutant amino acid in themodified position. The Logre was imple-
mented ad hoc according to the description of its algorithm.9
Mutation Assessor (Massessor) was launched at its web server,
and the results were obtained through its webAPI.
We ran all five tools on the four datasets described above, andwe
integrated their outputs as described in the following section. The
details on each tool’s version, the options we used to run each of
the tools, the databases that we searched for orthologous and
paralogous proteins, the implementation of the Logre algorithm,
and the automation of the MAPP are available in Table S1 of the
Supplemental Data.
Integrating the Output of Predictive Tools
After running the five tools on HumVar and HumDiv, we con-
structed the complementary cumulative distributions of the scores
of deleterious and neutral mutations produced by each tool. The
corresponding receiver operator characteristic (ROC) curves were
also built. In order to determine the optimal cutoff of each toolerican Journal of Human Genetics 88, 440–449, April 8, 2011 441
for the datasets—it had only been reported for Polyphen2, which
was the only tool that had previously classified these datasets—we
assayed the dependence of their accuracy with respect to their
sensitivity (Figure S1). For each tool, we selected as a cutoff the
score that produced the sensitivity yielding the maximum accu-
racy at classifying each dataset. For HumVar, for example, the
optimal cutoffs (as normalized scores: see below) were as follows:
SIFT, 0.85; Logre, 0.51; MAPP, 0.06; Polyphen2, 0.28; and Masses-
sor, 0.26.
The internal scores of the five predictive tools, although
different in nature, reflect the probability that an amino acid
change will be accepted at a given position of a protein sequence.
Whereas SIFT computes directly, from a multiple-sequence align-
ment, a probability that a given substitution takes place,14,15
PPH2 calculates an a posteriori probability that a mutation is dele-
terious.7 It makes this calculation on the basis of a number of
features, one of which is a substitution score from a multiple-
sequence alignment. On the other hand, the MAPP score for
a given amino acid represents the violation of physico-chemical
constraints at a position of the protein sequence.19 The Logre
computes the alteration in the fit of the protein domain where
the mutation is located to an HMM profile caused by the amino
acid change.9 Finally, Massessor scores amino acid substitutions
on the basis of the conservation of residues that define subfamilies
within protein families in a multiple-sequence alignment.18 In
order to operate with comparable scores, we normalized the
internal scores of MAPP, Logre, and Massessor to values between
0 and 1 and took the complement of the SIFT probability as the
normalized score of this tool.
For each mutation, let Ni be a binary term that takes value 1 if
the i-th tool succeeds at classifying the mutation as either delete-
rious or neutral; let Ci be another binary term that takes value 1
if the i-th tool classifies the mutation as deleterious and 0 other-
wise. Let Si be the normalized score produced by that tool. Finally,
let Pni and Ppi be the probabilities of finding a neutral or delete-
rious mutation, respectively, with a score greater than Si in the
given dataset, obtained from the complementary cumulative
distribution of the scores produced by the i-th tool. We assayed
four ways to integrate the outputs of the tools in these two data-
sets: a simple vote score (SVS), a simple average score (SAS), a
weighted vote score (WVS), and a weighted average score (WAS).
The SVS and the SAS of each mutation can be defined as follows:
SVS ¼
X
i
Ci ; SAS ¼
P
i
Si
P
i
Ni
:
The equation used for calculating the WVS would be
WVS ¼
P
i
Ci Wi
P
i
Wi
; where
Wi ¼ 1 Pni if Ci ¼ 1;
Wi ¼ 1 Ppi if Ci ¼ 0:
And, finally, the WAS can be obtained as follows:
WAS ¼
P
i
Si Wi
P
i
Wi
; where
Wi ¼ 1 Pni if Ci ¼ 1;
Wi ¼ 1 Ppi if Ci ¼ 0:
Note that the term 1 Pni corresponds to the probability that an
above-the-score (predicted deleterious) mutation is not a false
positive, given the complementary cumulative distribution of
scores exhibited by the i-th tool. This probability will increase
with the score of the mutations, and as it increases, the contribu-442 The American Journal of Human Genetics 88, 440–449, April 8, 2tion of Si to the WVS or WAS will grow. On the other hand, for
mutations predicted to be neutral, the lower Si,, the smaller the
term 1  Ppi,, which reflects the probability that the mutation
predicted to be neutral is not a false negative, and the lower the
contribution to the WVS or WAS. Also, the denominator of the
expression in both weighted approaches is the summation of
the weights, rather than the summation of methods that succeed
at classifying the mutation. These contributions may be thought
of as being also weighted. This ensures that the WVS and WAS
actually hold values between 0 and 1. See Figure S2 for further
details.Results
Combined Classification of Missense Mutations
The approach we designed in this work to integrate the
output of different methods that assess the effect of
missense SNVs can, in principle, be applied to any array
of suchmethods. To implement it, we selected a set of tools
that could be readily installed and run locally, queried
through a webAPI, or easily implemented. This screening
process yielded the five aforementioned tools. It is impor-
tant to point out, however, that the approach to this inte-
gration does not depend on the array of predictive tools
employed; both weighted and average scores (see below)
may be applied to a subset of these five tools or to an
altogether different set of them.
After running the five tools on every mutation in the
positive and negative sets of HumVar and HumDiv7 (see
Material and Methods), we found that 97.9% deleterious
and 97.3% neutral mutations of HumVar and 99.7% posi-
tive and 98.8% negative mutations of HumDiv could be
classified by at least three of the tools (Table 2 and
Figure S3). Therefore, it was feasible to design an approach
that combined the output of the five tools into one unified
result. We pursued this integration at two levels: classifica-
tion and score. At the first level, we integrated the classifi-
cations of different methods by using both an SVS and
a WVS. At the second, the internal scores calculated by
each method to achieve a classification were combined
through an SAS and a WAS.
The weights employed reflect how extreme a value of
score is within the complementary cumulative distribu-
tion produced by a given tool. For a predicted deleterious
mutation, the weight—the probability that it is not a false
positive—increases with the score, thus inflicting a higher
penalty on scores that are closer to the cutoff and lower
costs to scores closer to the tail of the complementary
cumulative distribution of true neutral mutations
(Figure S2). For a mutation predicted to be neutral, on
the other hand, the lower the score, the smaller the
weight—the probability that it is not a false negative—
and thus, the higher the penalization. (The actual comple-
mentary cumulative distributions of scores that were
produced by the five methods of classifying HumVar and
subsequently used for computing the weights used for
calculating the WAS are presented in Figure S4.)011
Table 2. Coverage of Mutations in HumVar and HumDiv by the Five Tools
Number of Methods Classifying a Mutation
HumVar HumDiv
Disease Related Polymorphisms Disease Related Changes Orthologs
at least 1 100% 100% 100% 100%
at least 2 100% 100% 100% 100%
at least 3 97.9% 97.3% 99.7% 98.8%
at least 4 90.3% 81.1% 95.2% 84.8%
all 58.1% 46.8% 73.2% 48.5%This way, if two methods produce the same score for
a mutation, more weight will be given to the positive
vote (or the above-cutoff score) of the tool for which the
complementary cumulative distributions of true delete-
rious and true neutral mutations are better separated.
Conversely, the below-cutoff score of this tool will get
a lower weight. This system of weights thus has the effect
of fine tuning the comparison of scores (or votes) from
different tools because the underlying probabilities depend
on the complementary cumulative distributions of scores
that a method produces for a given dataset.
For all deleterious and neutral mutations in HumVar and
HumDiv, we calculated the four aforementioned integrated
scores. Then, we constructed the ROC curves of these
indicators for both datasets (Figure 1; see also Figure S5)
and computed their accuracy at classifying them (Figure 2
and Figure S6). The accuracy of the five tools and the four
integrated scores in each dataset was computed at the sensi-
tivity fraction thatmaximized the success rate (seeMaterial
and Methods and Figure S1). The accuracies of the assayed
tools at classifying HumVar ranged from 69% to 77.1%,
and the integrated scores correctly classified between
76.3% and 88.2% of the mutations. Between 84.5% and
89.6%of themutations inHumDivwere correctly classified 0.2
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The Amby the four integrated scores. TheWAS achieved thehighest
accuracy values in both datasets.
Both the original five tools and the four integrated scores
were better at classifying HumDiv than HumVar. This
behavior came as no surprise given the composition of
both datasets. They contain disease-related SNVs as posi-
tive examples; however, whereas the negative examples
in HumVar are common human polymorphisms, HumDiv
contains observed amino acid changes in mammalian or-
thologous proteins. Because all the five tools (and, conse-
quently, the integrated results) are designed to distinguish
between amino acid changes that are probably deleterious
and those that are accepted in evolution, the negative
examples in HumDiv are as a rule awarded lower scores
than their HumVar counterparts, whose alterations are
not necessarily found in orthologous proteins. This is
why we give higher relevance to the results obtained
with HumVar (where the improvement of the WAS with
respect to the individual methods is more notable) and
use the weights computed from this dataset in the remain-
ing parts of this work. For the same reason, the comple-
mentary cumulative distributions of scores distributed
with the script that calculates the WAS (see last section of
the Discussion) correspond to HumVar mutations.massess
logre
pph2
MAPP
SIFT
SVS
WVS
SAS
WAS
Figure 1. ROC Curves Produced by the Five
Tools and the Four Integrated Scores with the
HumVar Dataset
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Figure 2. Accuracy with which the Five Tools
and the Four Integrated Scores Classify the
Hum Var Dataset
Green bars: accuracy of individual methods. Red
bars: accuracy of integrated scores.We recalculated the WAS for all HumVar mutations by
using the weights computed from the tools’ classification
of HumDiv.We have called this process cross-classification,
and we employed it as a means of validating the WAS
approach on a dataset different than the one used for
computing the weights. (The complementary cross-classifi-
cation was also performed.) Figure S7 presents the ROC
curves resulting from cross-classification of both datasets
along with the original ROC curves. It is apparent from
this graph that the accuracy of HumVar cross-classification
is practically equal to that of to its self-classification. On the
other hand, cross-classifying HumDiv decreases the accu-
racy of the WAS on this dataset by only approximately 2%.
We also performed a 10-fold cross-validation of the WAS
on HumVar (Figure S7). The ROC curve resulting from this
cross-validation shows that very little accuracy is lost when
the weights are computed from 90% of the mutations in
HumVar and used for classification of the remaining 10%.
Cancer Mutation Recurrence Correlates with WAS
Because theWAS exhibited the best performance in the task
of classifying the mutations in HumVar and HumDiv, we
then evaluated whether the WAS could be used as an indi-
cator of the importance of cancer-associated mutations.
For that we assessed how well it correlated with cancer
mutation recurrence. To perform the analysis, we sampled
four disjoint subsets of Cosmic mutations with increasing
recurrence:mutations appearing in only one sample,muta-
tions recurring in two to four samples, mutations recurring
in five to nine samples, and those appearing in ten or more
samples (see Material and Methods). We calculated two
values of WAS for each mutation by using the weights ob-
tained from the complementary cumulative distributions
of deleterious and neutral mutations in HumVar.
As presented in Figure 3, the subsets of Cosmic exhibited
significantly different WAS distributions, as detected by
the Wilcoxon-Mann-Whitney test. The subset of muta-444 The American Journal of Human Genetics 88, 440–449, April 8, 2011tions found in only one sample exhibited
a mean WAS of 0.538, whereas the muta-
tions recurring in ten or more samples pre-
sented a mean WAS of 0.706. The p value
corresponding to the comparison of the
extreme groups was 2.33 3 10143. In
contrast, neutral polymorphisms from
HumVar present a mean WAS of 0.236,
and their comparison to all groups of cancer
mutations produced p values smaller
than 10318.
We made the same comparisons by using
the WAS computed with the weights takenfrom HumDiv (Figure S8). We found that the mean WAS
of the four groups tended to be smaller, and the differences
were not so well marked as with the HumVar WAS. The
better results obtained with the HumVar WAS are most
likely explained by the deleterious mutations and neutral
polymorphisms in HumVar—and therefore the distribu-
tion of their scores—are more similar to highly recurrent
and nonrecurrent cancer mutations than the Mendelian-
disease-related mutations and orthologous amino acid
changes that compose HumDiv.
The WAS Correlates with the Biological Activity
of TP53 Mutants
In an attempt to determine whether theWAS could serve as
a good predictor of the impact of different missense muta-
tions on the biological activity of proteins, we examined
the correlation between the average WAS and the activity
of the mutant protein. For this analysis we used a dataset
composed of more than two thousand TP53 mutants and
their associated biological activity measured as the trans-
activation of transcription at four yeast promoters.
The mutants in the TP53 database were binned by their
biological activity (as a percentage of the wild-type) at four
yeast promoters, WAF1, MDM2, AIP1, and NOXA.31–33 We
formed ten bins by grouping the mutants with activity
between 0% and 10% of the wild-type, between 10%
and 20%, and so on. We then evaluated to what degree
the WAS of the mutations in each bin correlated with the
higher activity of the bin (Figure 4). We found that the
decrease in the ability of the p53 mutants to stimulate
transcription with respect to the wild-type shows a high
anti-correlation to the WAS of the bins. The Pearson’s
correlation coefficient ranged from 0.9 to 0.94.
A positional analysis of the WAS of mutants occurring in
the DNA binding domain of p53 revealed that positions
175, 176, 179, 196, 242, 248, 278, and 282 exhibited
mean values of WAS with p values below 0.005 (Figure 5).
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Figure 3. Comparison of the WAS of Four Disjoint Sets of Mutations from the Cosmic Database and the WAS of HumVar Neutral
Mutations
The five sets consist, respectively, of the neutral mutations in HumVar, the mutations appearing in only one sample (1), those appearing
in two to four samples (2–4), those appearing in five to nine samples (5–9), and those appearing in ten or more samples (10þ) in the
Cosmic database. The points represent the mean WAS; the error bars represent the standard error of the mean. The weights were
computed from the HumVar dataset. The p values resulting from the Wilcoxon-Mann-Whitney test of each group-group comparison
are shown in the graph. (All comparisons including neutral polymorphisms yielded p values smaller than 10318.)In other words, the probability that such mutations are
neutral is lower than 0.5%, as deduced from the comple-
mentary cumulative distribution of HumVar neutral
mutations.Discussion
Designing and Implementing a Consensus
Deleteriousness Score
In this work we integrated the output of five classifiers that
categorize SNVs as probably neutral or probably delete-
rious. Others have employed this idea in bioinformatics
to accomplish tasks such as the identification of functional
elements within the genome.34–36 We devised a simple
approach, consisting of classifying two very comprehen-
sive datasets of human mutations, both neutral and
deleterious, with five of themost widely employed compu-
tational tools for sorting missense SNVs.7–9,12–15,18,19,23
The basic idea behind the integration of these tools is to
take advantage of their possible complementary perfor-
mance at classifying missense SNVs. An example of this
complementarity can be appreciated in the fact that
although SIFT, PPH2, and Massessor misclassify between
24.7% and 46.4% of HumVar neutral mutations, only
13.5% are misclassified by all three (Figure S9).
We combined the outputs of SIFT, Logre, MAPP, PPH2,
and Massessor by using two naive (SVS and WVS) andThe Amtwo weighted approaches (SAS and WAS). We found that
the WAS performed better that the SAS in the task of
classifying missense mutations as neutral or deleterious,
as expected. On the other hand, the SVS actually outper-
forms its weighted counterpart by 2% in HumVar. All the
gain occurs at low scores, and it is most likely caused by
the different denominator used for calculating the SVS
and the WVS. Whereas the SVS divides the summation
by the number of tools that successfully classified the
mutation, the WVS divides it by the sum of their weights.
As a result, at lower scores—corresponding to mutations
classified as neutral by most methods—the SVS actually
receives a greater penalty than the WVS and separates
the populations of deleterious and neutral mutations
better.
The WAS attains an accuracy of 88.2% for classifying
HumVar and 89.6% for classifying HumDiv. It outperforms
all individual tools and the other three integrated scores at
this task. This behavior makes it the combination of choice
for integrating the output of tools aimed at classifying
the outcome of missense mutations. As cited in the
Results section, the higher accuracy reached by the Hum-
Div WAS is actually an artifact of the composition of the
dataset. Therefore, we recommend that the weights calcu-
lated from HumVar be used to compute the WAS of
missense SNVs, both for the task of classifying them as
deleterious or neutral, and for that of ranking their
deleteriousness.erican Journal of Human Genetics 88, 440–449, April 8, 2011 445
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Figure 4. Correlation between the WAS and the Biological Activity of Bins of TP53 Mutants
Mutants’ activity measured as their ability to trans-activate transcription at four yeast promoters (WAF1, MDM2, AIP1, and NOXA) is
given as a percent of the wild-type activity. The points represent the meanWAS; the error bars represent the standard error of the mean.We also tested the performance of the WAS at categoriz-
ing subsets of mutations classified by exactly the same
number of tools to make sure that the WAS was not biased
toward sets of mutations recognized by more tools.
Figure S10 shows that the ROC curves produced by the
WAS on the subsets of HumVar and HumDiv mutations
classified by exactly five tools are very similar to those of
the entire datasets. The accuracy of the WAS in the subset
of HumDiv mutations classified by only four tools is
slightly better than its accuracy for the whole dataset.
Probably a lower fraction of mutations incoherently classi-
fied by several tools appears within this subset than in the
entire dataset. (Analogous results were obtained for muta-
tions classified by exactly four tools.)
WAS Used as a Deleteriousness Score
For the above-stated reasons, we chose the WAS computed
fromHumVar weights to proceed to score sets of differently
recurring cancer mutations and p53 mutants (see Material
and Methods). We wanted to assess whether, in addition
toperformingwell at sortingneutral fromdeleteriousmuta-
tions, the WAS would behave as a good predictor of the
effect of different mutations on the biological activity of
the mutants. In other words, we intended to test whether
the WAS could be used as a deleteriousness score of muta-
tions. Theunderlyinghypothesiswas thatmore-deleterious
amino acid changes should coherently be awarded high
scores by all methods, thus resulting in higher WAS values.446 The American Journal of Human Genetics 88, 440–449, April 8, 2In agreement with this thought, we found that more-
recurrent cancer mutations possess significantly higher
WAS values than their nonrecurrent counterparts. More-
over, the average WAS increases with the number of
samples in which a mutation is found. It also correlates
very well with the decrease in biological activity of p53
mutants. Three of the positions with WAS p values below
5 3 103 (175, 248, and 282) correspond to known p53
mutation hotspots. Amino acid changes at the first and
last position are classified as ‘‘structural’’ mutations,
whereas the 248 position (occupied by an arginine in the
wild-type protein) is a ‘‘contact’’ residue.32,37,38 Changes
at these three positions result in mutants whose trans-acti-
vation capability is severely impaired (as shown in the
upper panels of Figure 4). Interestingly, the other five posi-
tions with significantly high average WAS, although not
recognized as p53 mutational hotspots, do harbor
mutants, which exhibit sharp decreases of their trans-acti-
vation capacity. Taken together, these results indicate that
the WAS may indeed serve as a good indicator of the
decrease in biological activity resulting from a missense
deleterious mutation.
Using Condel
Given the above results, we propose that research groups
interested in assessing the probability that a set of missense
SNVs is deleterious run the five tools used in this work
and integrate their resulting scores by using a WAS-type011
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Figure 5. Mutational Landscape of the C-Terminal Half of the DNA-Binding Domain of p53
The abscissa of all graphs represents the position within the sequence. The bottom graph depicts the meanWAS of mutants at each posi-
tion, and the other four graphs contain the mean biological activity, measured as the trans-activation of transcription at four yeast
promoters (WAF1, MDM2, AIP1, and NOXA, from top to bottom). Only 0.5% of the neutral mutations in HumVar score at or above
the WAS value marked by the red line in the bottom graph; vertical broken lines show the positions with mean WAS greater than
this value.approach. (To accomplish this first step, groups need not
download and install the five tools locally. Instead, they
may query each tool at its webserver; the URLs are listed
in the Web Resources.) This probability-based integration,
which relies on the consistency of the assessment made by
different methods, should be of interest, primarily to
groups embarked in genome-wide projects producing large
catalogs of missense SNVs. To facilitate the employment of
our integration approach, which we have named Condel,
we have made available a PERL script that computes the
WAS of missense mutations from the complementary
cumulative distributions of scores of deleterious and
neutral mutations in HumVar. This PERL script, along
with the files containing such complementary cumulative
distributions, is available from our group’s website (see
Web Resources).
Examples of projects that could benefit from the use of
Condel include The Cancer Genome Atlas, the Interna-
tional Cancer Genome Consortium, the 1000 Genomes
Project Consortium, and the sequencing of genomes
of patients affected by rare diseases. In particular, projects
of this latter type, which frequently require rankingThe Amde novo single-nucleotide variants found in exomic se-
quences by their potential effect on protein function,
should find Condel very useful.
The simplicity of Condel allows it to be easily modified
to include the output of new methods to the integrated
score or to change the datasets from which the weights
are calculated. The former requires only a modification of
the PERL script provided at our website and the calculation
of the complementary cumulative distributions corre-
sponding to the new tool, and the latter needs the recalcu-
lation of the complementary cumulative distributions. It
can be used with a subset of the five methods and yield
very good results, as shown in Figure S10.
Supplemental Data
The Supplemental Data contain ten figures and one table and can
be found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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